Novel Anti-cancer Compounds for Developing Combinatorial Therapies to Target Anoikis-Resistant Tumors

Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice

(2016) Vladimir N. Anisimov et al.   Aging-US

Cross talk Initiated by Endothelial Cells Enhances Migration and Inhibits Anoikis of Squamous Cell Carcinoma Cells through STAT3/Akt/ERK Signaling

(2015) Kathleen G. Neiva et al.   NEOPLASIA

RalBP1 Is Necessary for Metastasis of Human Cancer Cell Lines

(2015) Zhong Wu et al.   NEOPLASIA

Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer

(2011) Johnny Kao et al.   CANCER

Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells

(2011) H. Xu et al.   CLINICAL CANCER RESEARCH

Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis

(2011) S. S. Singhal et al.   MOLECULAR CANCER THERAPEUTICS

Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer

(2011) Bin Bao et al.   PLoS One

RLIP76, a Glutathione-Conjugate Transporter, Plays a Major Role in the Pathogenesis of Metabolic Syndrome

(2011) Jyotsana Singhal et al.   PLoS One

Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen species-mediated Bcl-2 downregulation

(2010) Varisa Pongrakhananon et al.   APOPTOSIS

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

(2010) Heather D. Brooks et al.   CANCER

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy

(2010) Xuerong Wang et al.   CANCER BIOLOGY & THERAPY

Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

(2010) S. A. Grossman et al.   CLINICAL CANCER RESEARCH

Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer

(2010) B. Sen et al.   CLINICAL CANCER RESEARCH

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

(2010) U. Banerji et al.   CLINICAL CANCER RESEARCH

The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors

(2010) Lokesh Dalasanur Nagaprashantha et al.   INTERNATIONAL JOURNAL OF CANCER

Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21

(2010) Yongci Zhang et al.   INVESTIGATIONAL NEW DRUGS

Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer

(2010) Nasser Altorki et al.   JOURNAL OF CLINICAL ONCOLOGY

Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis

(2010) Pawan Kumar et al.   Molecular Cancer

Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

(2010) S. L. Holbeck et al.   MOLECULAR CANCER THERAPEUTICS

KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

(2010) Young-Kwang Yoon et al.   MOLECULAR CARCINOGENESIS

Network medicine: a network-based approach to human disease

(2010) Albert-László Barabási et al.   NATURE REVIEWS GENETICS

Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice

(2010) Maxime Cazorla et al.   PLoS One

Biological Effects of a New Vacuolar-H,+-ATPase Inhibitor in Colon Carcinoma Cell Lines

(2009) Rosanna Supino et al.   Annals of the New York Academy of Sciences

SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2

(2009) Afshin Dowlati et al.   ANTI-CANCER DRUGS

Inhibition of the Sodium Potassium Adenosine Triphosphatase Pump Sensitizes Cancer Cells to Anoikis and Prevents Distant Tumor Formation

(2009) C. D. Simpson et al.   CANCER RESEARCH

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

(2009) T. Arumugam et al.   CANCER RESEARCH

Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells

(2009) Vivian W.Y. Lui et al.   CARCINOGENESIS

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment

(2009) A. Greenhough et al.   CARCINOGENESIS

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models

(2009) Claudio Festuccia et al.   ENDOCRINE-RELATED CANCER

Personalized cancer diagnostics and therapeutics

(2009) Dimitrios H Roukos   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Role of RLIP76 in doxorubicin resistance in lung cancer (Review)

(2009) Singhal   INTERNATIONAL JOURNAL OF ONCOLOGY

Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1

(2009) Marie-Josée Demers et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Small Molecule Integrin Antagonists in Cancer Therapy

(2009) Mayra Paolillo et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

A Twist-Snail Axis Critical for TrkB-Induced Epithelial-Mesenchymal Transition-Like Transformation, Anoikis Resistance, and Metastasis

(2009) M. A. Smit et al.   MOLECULAR AND CELLULAR BIOLOGY

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

(2009) K. Thress et al.   MOLECULAR CANCER THERAPEUTICS

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL

Racial Disparity in Breast Cancer and Functional Germ Line Mutation in Galectin-3 (rs4644): A Pilot Study

(2008) V. Balan et al.   CANCER RESEARCH

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

(2008) Stuart Thomson et al.   CLINICAL & EXPERIMENTAL METASTASIS

Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiforme

(2008) David A Reardon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Frequencies of NRAS and BRAF Mutations Increase from the Radial to the Vertical Growth Phase in Cutaneous Melanoma

(2008) Victoria R. Greene et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Active N-Ras and B-Raf Inhibit Anoikis by Downregulating Bim Expression in Melanocytic Cells

(2008) Nathaniel B. Goldstein et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

An α5β1 integrin inhibitor attenuates glioma growth

(2008) Katrin Färber et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

 v 3 Integrin-Mediated Drug Resistance in Human Laryngeal Carcinoma Cells Is Caused by Glutathione-Dependent Elimination of Drug-Induced Reactive Oxidative Species

(2008) A. Brozovic et al.   MOLECULAR PHARMACOLOGY

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

DxS Ltd

(2008) Joanne Cross   PHARMACOGENOMICS

Getting Started in Biological Pathway Construction and Analysis

(2008) Ganesh A Viswanathan et al.   PLoS Computational Biology